PREFERRED STOCK PURCHASE
AGREEMENT
PROGENTIX ORTHOBIOLOGY,
B.V.
The Sellers listed on
Schedule A attached hereto
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.
|
|
|
SALE AND
TRANSFER OF THE INITIAL SHARES
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.1
|
|
|
Sale and
Transfer of the Initial Shares
|
|
|
2
|
|
|
|
|
|
1.2
|
|
|
Closing of the
Purchase of the Initial Shares
|
|
|
2
|
|
|
|
|
|
1.3
|
|
|
Notary
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.
|
|
|
REPRESENTATIONS
AND WARRANTIES OF THE SELLERS WITH RESPECT TO THE SELLER
SHARES
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.1
|
|
|
Authority;
Execution and Delivery; Enforceability
|
|
|
3
|
|
|
|
|
|
2.2
|
|
|
Non-Contravention
|
|
|
3
|
|
|
|
|
|
2.3
|
|
|
Title to Seller
Shares
|
|
|
3
|
|
|
|
|
|
2.4
|
|
|
Consents and
Approvals
|
|
|
4
|
|
|
|
|
|
2.5
|
|
|
Litigation and
Claims
|
|
|
4
|
|
|
|
|
|
2.6
|
|
|
No
Finder
|
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.
|
|
|
REPRESENTATIONS
AND WARRANTIES OF THE COMPANY
|
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.1
|
|
|
Organization
and Good Standing
|
|
|
4
|
|
|
|
|
|
3.2
|
|
|
Authority; No
Conflict
|
|
|
5
|
|
|
|
|
|
3.3
|
|
|
Capitalization
|
|
|
6
|
|
|
|
|
|
3.4
|
|
|
Financial
Statements
|
|
|
6
|
|
|
|
|
|
3.5
|
|
|
Books and
Records
|
|
|
6
|
|
|
|
|
|
3.6
|
|
|
Title to
Properties; Encumbrances
|
|
|
7
|
|
|
|
|
|
3.7
|
|
|
Condition and
Sufficiency of Assets
|
|
|
7
|
|
|
|
|
|
3.8
|
|
|
Accounts
Receivable
|
|
|
8
|
|
|
|
|
|
3.9
|
|
|
Inventory
|
|
|
8
|
|
|
|
|
|
3.10
|
|
|
No Undisclosed
Liabilities
|
|
|
8
|
|
|
|
|
|
3.11
|
|
|
Taxes
|
|
|
8
|
|
|
|
|
|
3.12
|
|
|
No Material
Adverse Change
|
|
|
10
|
|
|
|
|
|
3.13
|
|
|
Pensions
|
|
|
10
|
|
|
|
|
|
3.14
|
|
|
Legal
Proceedings; Orders
|
|
|
10
|
|
|
|
|
|
3.15
|
|
|
Absence of
Certain Changes and Events
|
|
|
11
|
|
|
|
|
|
3.16
|
|
|
Contracts; No
Defaults
|
|
|
12
|
|
|
|
|
|
3.17
|
|
|
Insurance
|
|
|
14
|
|
|
|
|
|
3.18
|
|
|
Environmental
Matters
|
|
|
16
|
|
|
|
|
|
3.19
|
|
|
Employees
|
|
|
17
|
|
|
|
|
|
3.20
|
|
|
Intellectual
Property
|
|
|
17
|
|
|
|
|
|
3.21
|
|
|
Certain
Payments
|
|
|
21
|
|
|
|
|
|
3.22
|
|
|
Authorizations;
Regulatory Compliance
|
|
|
21
|
|
|
|
|
|
3.23
|
|
|
Products;
Product Liability
|
|
|
23
|
|
|
|
|
|
3.24
|
|
|
Customers and
Suppliers
|
|
|
23
|
|
|
|
|
|
3.25
|
|
|
Capital
Expenditures
|
|
|
24
|
|
|
|
|
|
3.26
|
|
|
Relationships
with Affiliates
|
|
|
24
|
|
|
|
|
|
3.27
|
|
|
Brokers
|
|
|
24
|
|
|
|
|
|
3.28
|
|
|
Disclosure
|
|
|
24
|
|
-i-
TABLE OF CONTENTS
(continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.
|
|
|
REPRESENTATIONS
AND WARRANTIES OF PURCHASER
|
|
|
24
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.1
|
|
|
Organization
and Good Standing
|
|
|
24
|
|
|
|
|
|
4.2
|
|
|
Authority; No
Conflict
|
|
|
25
|
|
|
|
|
|
4.3
|
|
|
Certain
Proceedings
|
|
|
25
|
|
|
|
|
|
4.4
|
|
|
Brokers
|
|
|
26
|
|
|
|
|
|
4.5
|
|
|
No Other
Representations
|
|
|
26
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.
|
|
|
CONDUCT OF
BUSINESS DURING THE OPTION PERIOD
|
|
|
26
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.1
|
|
|
Conduct of
Business of the Company
|
|
|
26
|
|
|
|
|
|
5.2
|
|
|
Clinical
Trials
|
|
|
29
|
|
|
|
|
|
5.3
|
|
|
FDA Approval
Matters
|
|
|
29
|
|
|
|
|
|
5.4
|
|
|
Payment of
Taxes, Etc
|
|
|
30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ADDITIONAL
AGREEMENTS
|
|
|
30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6.1
|
|
|
Access to
Properties and Information
|
|
|
30
|
|
|
|
|
|
6.2
|
|
|
Notification of
Certain Matters
|
|
|
30
|
|
|
|
|
|
6.3
|
|
|
Confidentiality; Publicity
|
|
|
30
|
|
|
|
|
|
6.4
|
|
|
Use of Proceeds
from the Facility
|
|
|
31
|
|
|
|
|
|
6.5
|
|
|
Monthly and
Quarterly Statements
|
|
|
31
|
|
|
|
|
|
6.6
|
|
|
Audits
|
|
|
31
|
|
|
|
|
|
6.7
|
|
|
Recapitalization
|
|
|
31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7.
|
|
|
INDEMNIFICATION; REMEDIES
|
|
|
31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7.1
|
|
|
Survival; Right
to Indemnification Not Affected by Knowledge
|
|
|
31
|
|
|
|
|
|
7.2
|
|
|
Indemnification
and Payment of Damages by Sellers
|
|
|
32
|
|
|
|
|
|
7.3
|
|
|
Indemnification
and Payment of Damages by Purchaser
|
|
|
33
|
|
|
|
|
|
7.4
|
|
|
Limitations on
Indemnification
|
|
|
33
|
|
|
|
|
|
7.5
|
|
|
Procedure for
Indemnification—Third Party Claims
|
|
|
34
|
|
|
|
|
|
7.6
|
|
|
Procedure for
Indemnification—Other Claims
|
|
|
35
|
|
|
|
|
|
7.7
|
|
|
Remedies
Exclusive
|
|
|
35
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8.
|
|
|
CLOSING
DELIVERABLES
|
|
|
35
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8.1
|
|
|
Closing
Deliverables of the Company
|
|
|
35
|
|
|
|
|
|
8.2
|
|
|
Closing
Deliverables of the Purchaser
|
|
|
37
|
|
|
|
|
|
8.3
|
|
|
Closing
Deliverables of the Parties
|
|
|
38
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9.
|
|
|
GENERAL
PROVISIONS
|
|
|
38
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9.1
|
|
|
Expenses
|
|
|
38
|
|
|
|
|
|
9.2
|
|
|
Notices
|
|
|
38
|
|
|
|
|
|
9.3
|
|
|
Jurisdiction;
Service of Process
|
|
|
39
|
|
|
|
|
|
9.4
|
|
|
Dispute
Resolution
|
|
|
39
|
|
|
|
|
|
9.5
|
|
|
Waiver
|
|
|
40
|
|
|
|
|
|
9.6
|
|
|
Entire
Agreement and Modification
|
|
|
41
|
|
|
|
|
|
9.7
|
|
|
Assignments,
Successors, and No Third-Party Rights
|
|
|
41
|
|
-ii-
TABLE OF CONTENTS
(continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9.8
|
|
|
Release of
Claims
|
|
|
41
|
|
|
|
|
|
9.9
|
|
|
Severability
|
|
|
41
|
|
|
|
|
|
9.10
|
|
|
Section
Headings, Construction
|
|
|
42
|
|
|
|
|
|
9.11
|
|
|
Time of
Essence
|
|
|
42
|
|
|
|
|
|
9.12
|
|
|
Governing
Law
|
|
|
42
|
|
|
|
|
|
9.13
|
|
|
Counterparts
|
|
|
42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.
|
|
DEFINITIONS
|
|
|
|
42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Index of Other
Defined Terms:
|
|
|
52
|
|
-iii-
|
|
|
|
|
|
|
Sellers
Schedule
|
|
|
|
|
|
|
|
Option Purchase
Agreement
|
|
|
|
Facility
Agreement
|
|
|
|
Amended
Articles of Association
|
|
|
|
Notarial
Deed
|
|
|
|
Form of
Proprietary Inventions Agreement
|
|
|
|
Opinion of
Counsel
|
|
|
|
Distribution
Agreement
|
|
|
|
Revos License
Agreement
|
|
|
|
Pledge
Agreement
|
|
|
|
Shareholders’ Agreement
|
|
|
|
Founders’
Non-competition Agreement (Bruijn)
|
|
|
|
Founders’
Non-competition Agreement (Blitterswijk)
|
|
|
|
Investor
Non-competition Agreement
|
-iv-
PREFERRED STOCK PURCHASE
AGREEMENT
THIS PREFERRED
STOCK PURCHASE AGREEMENT (“ Agreement
”) is made as of January 13, 2009 (the “
Effective Date ”), by and among NuVasive, Inc.,
a Delaware corporation (“ Purchaser ”),
Progentix Orthobiology B.V., a company organized under the laws of
the Netherlands (the “ Company ”), and
the shareholders of the Company as set forth on
Schedule A attached hereto (each a “
Seller ,” and collectively, the “
Sellers ,” and along with the Company, the
“ Seller Parties ”).
The Sellers desire
to sell, and Purchaser desires to purchase, 7,200 ordinary
shares, €
1.00 par value per share, and 1,600
cumulative preference shares, €
1.00 par value per share, of the
Company, for an aggregate purchase price of $10,000,000, which
shares represent, immediately after such issuance, forty percent
(40%) of the outstanding capital stock of the Company on a
fully-diluted basis (the “ Initial Shares
”).
Purchaser and the
Seller Parties have entered into an Option Purchase Agreement,
dated as of the date hereof, in the form attached hereto as
Exhibit A (the “ Option Purchase
Agreement ”), pursuant to which, and subject to
certain exceptions set forth therein, (i) Purchaser may elect,
in its sole discretion, to cause the Sellers to sell to Purchaser
the remaining issued and outstanding shares of the capital stock of
the Company held by the Sellers (the “ Remaining
Shares , ” and along with the Initial Shares,
the “ Seller Shares ”) upon delivery of a
Purchase Election Notice (as defined therein) to the Sellers’
Representative (as defined in the Option Purchase Agreement) at any
time between the second anniversary of the date of the Option
Purchase Agreement and the fourth anniversary thereof (the “
Call Option Period ”), and (ii) Purchaser
shall be obligated to purchase from the Sellers all of the
Remaining Shares in the event (A) the Sellers’
Representative (as defined in the Option Purchase Agreement)
delivers a Milestone Completion Notice (as defined therein) to
Purchaser at any time between the date of the Option Purchase
Agreement and the second anniversary thereof (the “ Put
Option Period ”) or (B) Purchaser’s ***
(as defined in the Option Purchase Agreement) is greater than ***
at any time during the Call Option Period. Any purchase of the
Remaining Shares by the Purchaser pursuant to the Option Purchase
Agreement shall be referred to herein as an “
Acquisition .” The period from the date of the
Option Agreement through the expiration of the Call Option Period
shall be referred to herein as the “ Option
Period .”
In connection with
this Agreement and the Option Purchase Agreement, Purchaser has
entered into a Facility Agreement with the Company, dated as of the
date hereof, in the form attached hereto as Exhibit B
(the “ Facility Agreement ”) pursuant to
which Purchaser is lending up to $5,000,000 to the
Company.
In connection with
this Agreement and the Option Purchase Agreement, pursuant to a
notarial deed of amendment to the Company’s Articles of
Association in the form attached hereto as Exhibit C
(the “ Amended Articles ”), which
includes among other things, the creation
|
|
|
|
***
|
|
Portions of
this page have been omitted pursuant to a request for Confidential
Treatment filed separately with the Commission.
|
of cumulative
preference shares A (the “ Series A Preferred
Stock ”) and cumulative preference shares B (the
“ Series B Preferred Stock ”), and
pursuant to the execution of the notarial deed with respect to the
Amended Articles, (i) the cumulative preference shares held by
the Sellers shall be converted into shares of Series A
Preferred Stock, and (ii) the Initial Shares purchased by
Purchaser pursuant to the terms herein shall be converted into
shares of Series B Preferred Stock, such that Purchaser will
own shares of the Series B Preferred Stock, representing,
immediately after such issuance, forty percent (40%) of the
outstanding capital stock of the Company on a fully-diluted basis
(the “ Recapitalization ”). The Company
has filed a declaration of no-objection with the Dutch Ministry of
Justice with respect to the Amended Articles.
The parties,
intending to be legally bound, agree as follows:
1. SALE AND
TRANSFER OF THE INITIAL SHARES .
1.1 Sale and
Transfer of the Initial Shares.
(a) On
the Closing Date (as defined below), subject to the conditions set
forth in this Section 1 , Purchaser or its designee
shall purchase, and the Sellers shall sell and issue to Purchaser,
the Initial Shares for the aggregate purchase price of $10,000,000
(the “ Purchase Price ”) as set forth on
Schedule A attached hereto. At the Closing (as defined
below), Purchaser shall transfer (i) an amount of cash (in
United States dollars of immediately available funds) equal to the
Purchase Price minus the Seller Funded Expenses (the “
Upfront Payment ”) to the third party account of
the Notary in accordance with the instructions in the Notary
Instruction Letter, and (ii) on behalf of the Sellers, the
amounts set forth on the Estimated Closing Certificate to the
persons listed therein.. Prior to the transfer of the Initial
Shares, the Notary shall hold the Upfront Payment on behalf of
Purchaser. After the transfer of the Initial Shares, the Notary
shall hold the Upfront Payment on behalf of the Sellers. As soon as
possible after the Closing, but in any event within one
(1) Business Day of the Closing Date, the Notary shall pay to
the Sellers an amount equal to the Upfront Payment, pursuant to the
allocation set forth on Schedule A attached hereto (the
“ Pro Rata Allocation ”)
(b) The
parties acknowledge and agree that the aggregate fair market value
of the Initial Shares as of the Closing Date is equal to the
Purchase Price for the Initial Shares, and the parties agree to
file all Tax Returns in a manner consistent with this sentence and
not to take any Tax position inconsistent with this
sentence.
1.2 Closing of
the Purchase of the Initial Shares. The closing of the purchase
and sale of the Initial Shares (the “ Closing
”) shall take place at the offices of DLA Piper Nederland
N.V., ‘Meerparc’, Amstelveenseweg 638, 1081 JJ
Amsterdam, the Netherlands, as soon as practicable, or at such
other time, date and place as are mutually agreed upon by the
Company and Purchaser (the “ Closing Date
”). At the Closing, the Notary shall execute the deed of
transfer of the Initial Shares through the notarial deed in the
form substantially attached hereto as Exhibit D .
Immediately thereafter, the Notary shall transfer the Upfront
Payment to the Sellers, all in accordance with the instruction
letter from the Notary.
2
1.3 Notary
. The Seller Parties are aware that the Notary is a civil law
notary working at DLA Piper Nederland N.V., the firm that advises
Purchaser in respect of the matters set out in this Agreement. With
reference to the Code of Conduct ( Verordening beroeps- en
gedragsregels ) established by the Royal Notarial Professional
Organization ( Koninklijke Notariële Beroepsorganisatie
), parties hereby acknowledge and confirm that (i) the Notary
shall execute any and all deeds related to the Closing Documents;
and (ii) Purchaser is assisted and represented by DLA Piper
Nederland N.V. in relation to the Closing Documents and any other
agreements that may be concluded, or disputes that may arise, in
connection therewith.
2.
REPRESENTATIONS AND WARRANTIES OF THE SELLERS WITH RESPECT TO
THE SELLER SHARES
Each Seller,
severally but not jointly, hereby represents and warrants to
Purchaser as to such Seller and the Seller Shares owned by such
Seller, as of the Effective Date and as of the Closing Date, as set
forth below. Each exception to such representations and warranties
set forth in the Seller Parties Disclosure Schedule is identified
by reference to, or has been grouped under a heading referring to,
a specific section of this Agreement, and the disclosures in any
section or subsection of the Seller Parties Disclosure Schedule
shall qualify other sections and subsections in this Agreement to
the extent it is reasonably apparent from a reading of the
disclosure that such disclosure is applicable to such other
sections and subsections.
2.1 Authority;
Execution and Delivery; Enforceability. Each Seller has full
power, authority and capacity to execute and deliver this Agreement
and to perform such Seller’s respective obligations hereunder
and to consummate the transactions contemplated hereby. This
Agreement has been duly executed and delivered by such Seller and
constitutes the legal, valid and binding obligation of such Seller
enforceable against such Seller in accordance with its terms,
subject to bankruptcy and other similar Legal Requirements of
general applicability relating to or affecting creditors’
rights and to general equity principles.
2.2
Non-Contravention. The execution and delivery of this
Agreement by such Seller does not, and the consummation of the
transactions contemplated hereby and compliance with the terms
hereof, will not (or would not with the giving of notice or the
passage of time):
(a) constitute
a default under or a violation or breach (with or without notice)
of, result in the acceleration of any obligation under, any
provision of any contract or other instrument to which such Seller
is a party or result in the termination or revocation of any
authorization held by such Seller or the Company necessary to the
ownership of the Seller Shares or the operation of the business of
the Company;
(b) violate
any Order or any Legal Requirement affecting such Seller;
or
(c) result
in the creation of any Encumbrance on the Seller Shares.
2.3 Title to
Seller Shares. Each Seller is and will be on the Closing Date
the holder and beneficial owner of the Seller Shares owned by such
Seller. The Seller Shares owned by such Seller as of the Effective
Date are as set forth on Part 2.3 of the Seller Parties
Disclosure Schedule. Each Seller has good and valid title to the
Seller Shares owned by such Seller as set forth on Part 2.3 of the
Seller Parties Disclosure Schedule, free and clear of all
Encumbrances.
3
At the Closing,
each Seller will transfer legal and beneficial, good and valid
title to each of the Initial Shares owned by such Seller, free and
clear of all Encumbrances. No Seller is currently bound by any
contract, agreement, arrangement, commitment or understanding
(written or oral) with, and has not granted any option or right
currently in effect or which would arise after the Effective Date,
any Person other than Purchaser with respect to the acquisition of
any of Initial Shares.
2.4 Consents
and Approvals. Except as set forth in the Seller Parties
Disclosure Schedule, no consent, approval, waiver, license, permit,
order or authorization of, or registration, declaration or filing
with, any Governmental Body, and no consent, approval, waiver or
other similar authorization of any other Person (including, without
limitation, any Person who is a party to a Contract binding on or
affecting the Company or any Subsidiary), is required to be
obtained by or on behalf of such Sellers as a result of, or in
connection with, or as a condition of the lawful execution,
delivery and performance of this Agreement or the consummation of
the transactions contemplated hereby.
2.5 Litigation
and Claims. There is no Action pending or, to the Knowledge of
such Seller, Threatened, against or affecting such Seller that
could reasonably be expected to affect such Seller’s ability
to consummate the transactions contemplated hereby.
2.6 No
Finder. Except as set forth in the Seller Parties Disclosure
Schedule, neither such Seller nor any party acting on such
Seller’s behalf has paid or become obligated to pay any fee
or commission to any broker, finder or intermediary for or on
account of the transactions contemplated hereby, and the Company
will not be liable or obligated in any way whatsoever with respect
to any such fee or commission.
3.
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company hereby
represents and warrants to Purchaser, as of the Effective Date and
as of the Closing Date, as set forth below. Each exception to such
representations and warranties set forth in the Seller Parties
Disclosure Schedule is identified by reference to, or has been
grouped under a heading referring to, a specific section of this
Agreement, and the disclosures in any section or subsection of the
Seller Parties Disclosure Schedule shall qualify other sections and
subsections in this Agreement to the extent it is reasonably
apparent from a reading of the disclosure that such disclosure is
applicable to such other sections and subsections.
3.1
Organization and Good Standing .
(a) Part 3.1
of the Seller Parties Disclosure Schedule contains a complete and
accurate list for the Company of its name, its jurisdiction of
incorporation, other jurisdictions in which it is authorized to do
business, and its capitalization (including the identity of each
stockholder and the number of shares held by each). The Company is
a corporation duly organized, validly existing, and in good
standing under the laws of its jurisdiction of incorporation, with
full corporate power and authority to conduct its business as it is
now being conducted, to own or use the properties and assets that
it purports to own or use, and to perform all its obligations under
Applicable Contracts. The Company is a private company with limited
liability duly qualified to do business as a foreign corporation
and is in good standing under the
4
laws of each
state or other jurisdiction in which either the ownership or use of
the properties owned or used by it, or the nature of the activities
conducted by it, requires such qualification, except where the
failure to be so qualified would not reasonably be expected to have
a Material Adverse Effect.
(b) The
Company made available to Purchaser in the Data Room copies of the
Organizational Documents of the Company, as currently in
effect.
3.2 Authority;
No Conflict .
(a) The
Closing Documents to which the Company is a party have been
authorized by the board of directors (“ Board of
Directors ”) of the Company and, to the extent
required, by the shareholders of the Company. Upon the execution
and delivery by the Company of such Closing Documents, such Closing
Documents will constitute the legal, valid, and binding obligations
of the Company, enforceable against it in accordance with their
respective terms, subject to bankruptcy and other similar Legal
Requirements of general applicability relating to or affecting
creditor’s rights and to general equity principles. The
execution and delivery of such Closing Documents by the Company and
the performance of the Contemplated Transactions by it does not
conflict with any provision of the Organizational Documents of the
Company.
(b) Neither
the execution and delivery of this Agreement nor the consummation
or performance of any of the Contemplated Transactions will,
directly or indirectly (with or without notice or lapse of
time):
(i) contravene,
conflict with, or result in a violation of (A) any provision
of the Organizational Documents of the Company, or (B) any
resolution adopted by the board of directors or the shareholders of
the Company;
(ii) contravene,
conflict with, or result in a violation of, or give any
Governmental Body or other Person the right to challenge any of the
Contemplated Transactions or to exercise any remedy or obtain any
relief under, any Legal Requirement or any Order to which the
Company, or any of the assets owned or used by the Company, may be
subject;
(iii) contravene,
conflict with, or result in a violation of any of the terms or
requirements of, or give any Governmental Body the right to revoke,
withdraw, suspend, cancel, terminate, or modify, any Governmental
Authorization that is held by the Company or that otherwise relates
to the business of, or any of the assets owned or used by, the
Company;
(iv) cause
the Company to become subject to, or to become liable for the
payment of, any Tax;
(v) cause
any of the assets owned by the Company to be reassessed or revalued
by any taxing authority or other Governmental Body;
(vi) contravene,
conflict with, or result in a violation or breach of any provision
of, or give any Person the right to declare a default or exercise
any remedy under, or to
5
accelerate the
maturity or performance of, or to cancel, terminate, or modify, any
Applicable Contract; or
(vii) result
in the imposition or creation of any Encumbrance upon or with
respect to any of the assets owned or used by the Company, other
than Permitted Encumbrances.
Except as set
forth in Part 3.2 of the Disclosure Schedule the Company is
not nor will it be required to give any notice to or obtain any
Consent from any Person in connection with the execution and
delivery of this Agreement or the consummation or performance of
any of the Contemplated Transactions.
3.3
Capitalization . As of immediately prior to the Closing
(without giving effect to the Recapitalization), the authorized
equity securities of the Company consist of 60,000 ordinary shares,
par value €
1 per share, of which 18,000 shares
are issued and outstanding and 30,000 cumulative preference shares,
par value €
1 per share, of which 4,000 shares
are issued and outstanding. No shares or classes of the
Company’s capital are reserved for issuance. No reference to
any purported Encumbrance appears in the shareholders’
register of the Company. All of the outstanding equity securities
of the Company have been duly authorized and validly issued and are
fully paid. Except as set forth in Part 3.3 of the Seller
Parties Disclosure Schedule, there are no Contracts relating to the
issuance, sale, transfer or voting of any issued or issuable equity
securities or other securities (including, but not limited, to any
options, stock appreciation rights, warrants or other instruments
or securities exercisable or exchangeable for, or convertible into,
equity securities) of the Company. None of the outstanding equity
securities or other securities of the Company was issued in
violation of any Legal Requirement. The Company does not own, nor
does it have any Contract to acquire, any equity securities or
other securities of any Person or any direct or indirect equity or
ownership interest in any other business. The Company does not have
any Subsidiaries.
3.4 Financial
Statements . The Company has made available to Purchaser in the
Data Room the unaudited balance sheet of the Company and the
related unaudited statements of income, changes in
stockholders’ equity, and cash flow balance sheet of the
Company as of December 31 , 2008 (the “
Balance Sheet ”) and the related unaudited
statements of income, changes in shareholders’ equity, and
cash flow for the twelve (12) months then ended (collectively,
the “ Financial Statements ”), including
in each case the notes thereto (except that the unaudited Financial
Statements may not contain all required footnotes and the interim
Financial Statements are subject to year-end adjustments). The
Financial Statements fairly present in all material respects the
financial condition and the results of operations, changes in
stockholders’ equity, and cash flow of the Company as at the
respective dates of and for the periods referred to in the
Financial Statements. The Financial Statements referred to in this
Section 3.4 reflect the consistent application of such
accounting principles throughout the periods involved, except as
disclosed in the notes to such Financial Statements. No financial
statements of any Person other than the Company are required to be
included in the consolidated financial statements of the
Company.
3.5 Books and
Records . The books and records of the Company, all of which
have been made available to Purchaser in the Data Room, are
complete and correct in all material
6
respects and
have been maintained in accordance with sound business practices in
the Netherlands, including the maintenance of an adequate system of
internal controls. The minute books of the Company contain
materially accurate and complete records of all meetings held of,
and corporate action taken by, the stockholders, the Board of
Directors and the Supervisory Board of Directors of the Company,
and no meeting of any such stockholders, Board of Directors, or
committee has been held for which minutes have not been prepared
and are not contained in such minute books. At the Closing, all of
those books and records will be in the possession of the
Company.
3.6 Title to
Properties; Encumbrances . The Company does not currently own,
nor has it ever owned (a) any real property, (b) any
leasehold interests or (c) any buildings, plants, structures
and/or equipment. Part 3.6 of the Seller Parties Disclosure
Schedule contains a complete and accurate list of all (A) the
Assets that the Company purports to own, including all of the
properties and assets reflected in the Balance Sheet (except for
assets held under capitalized leases disclosed or not required to
be disclosed in Part 3.6 of the Seller Parties Disclosure
Schedule and personal property sold since the date of the Balance
Sheet, as the case may be, in the Ordinary Course of Business), and
(B) all of the properties and assets purchased or otherwise
acquired by the Company since the date of the Balance Sheet (except
for personal property acquired and sold since the date of the
Balance Sheet in the Ordinary Course of Business and consistent
with past practice), which subsequently purchased or acquired
properties and assets (other than inventory and short-term
investments) are listed in Part 3.6 of the Seller Parties
Disclosure Schedule. The Company is the sole owner and has good and
marketable title (or leasehold title, as the case may be) to the
Assets free and clear of all Encumbrances, and the Assets reflected
in the Balance Sheet are free and clear of all Encumbrances and are
not, in the case of real property, subject to any rights of way,
building use restrictions, exceptions, variances, reservations, or
limitations of any nature except, with respect to all such
properties and assets, (i) mortgages or security interests
shown on the Balance Sheet as securing specified liabilities or
obligations, with respect to which no default (or event that, with
notice or lapse of time or both, would constitute a default)
exists, (ii) mortgages or security interests incurred in
connection with the purchase of property or assets after the date
of the Balance Sheet (such mortgages and security interests being
limited to the property or assets so acquired), with respect to
which no default (or event that, with notice or lapse of time or
both, would constitute a default) exists, (iii) liens for current
taxes not yet due, and (iv) Encumbrances pursuant to the
Pledge Agreement (as defined below) or the Facility Agreement and
(v) Encumbrances incurred in the Ordinary Course of the
Business, consistent with past practice, or created by the express
provisions of the Contracts, each of the type identified on
Part 3.6 of the Seller Parties Disclosure Schedule (together,
the “ Permitted Encumbrances ”). All such
assets are suitable for the uses to which they are being put or
have been put in the Ordinary Course of Business and are in good
working order, ordinary wear and tear excepted.
3.7 Condition
and Sufficiency of Assets . Except as set forth on
Part 3.7 of the Seller Parties Disclosure Schedule, the Assets
are all assets of the Company used in or related to the processing
and manufacturing of the Products. Xpand Biotechnology B.V., a
private company with limited liability (“ Xpand
”), transferred to the Company the Company Proprietary Rights
and prior to such transfer of the Company Proprietary Rights, Xpand
was the sole and rightful owner of the Company Proprietary Rights.
Except as set forth on Part 3.7 of the Seller Parties
Disclosure Schedule, the Assets and the Company Proprietary Rights
of the Company
7
constitute all
of the assets, property, real personal or mixed, tangible or
intangible, of the Company used in or held for use in for the
operation of the Business as presently conducted.
3.8 Accounts
Receivable . The Company currently has no accounts receivable,
nor has it previously had any accounts receivable prior to the
Closing Date.
3.9
Inventory . The Company currently has no inventory, nor has
it previously had any inventory prior to the Closing
Date.
3.10 No
Undisclosed Liabilities . The Company has no liabilities or
obligations of any nature (whether known or unknown and whether
absolute, accrued, contingent, or otherwise), except for (a)
liabilities or obligations reflected or reserved against in the
Balance Sheet, (b) liabilities or obligations incurred since
the Balance Sheet Date in the Ordinary Course of Business, (c)
liabilities of a type or nature not required to be reflected in the
Financial Statements, which are not material, individually or in
the aggregate, or (d) liabilities or obligations set forth in
Part 3.10 of the Seller Parties Disclosure Schedule. Except as set
forth in Part 3.10 of the Seller Parties Disclosure Schedule
the Company is not a guarantor or indemnitor of any Indebtedness of
any other Person.
(a) The
Company has paid on a timely basis all Taxation that was due and
payable on or before the Closing Date. The unpaid taxes of the
Company for all Tax periods through the Balance Sheet Date do not
exceed the accruals and reserves for Taxation (excluding accruals
and reserves for deferred Taxation established to reflect timing
differences between book and Tax income) set forth on the Balance
Sheet.
(b) All
notices and returns required to have been given or made, have been
properly and duly submitted by the Company to the relevant
Governmental Body and all information, notices, computations and
returns submitted to such Governmental Body are true, accurate and
complete and are not the subject of any dispute nor are likely to
become the subject of any dispute with such Governmental Body. The
Company has not been informed by any Governmental Body that such
Governmental Body formally asserts that the Company was required to
file any Tax Return that was not filed, and, to the Sellers’
Knowledge, no such assertion is planned by any Governmental Body.
The Company has not (i) waived any statute of limitations with
respect to Taxation, (ii) requested any extension of time
within which to file any Tax Return, or (iii) executed or
filed any power of attorney with any taxing authority. All records
that the Company is required to keep for Taxation purposes, have
been duly kept and are available for inspection at the Company
premises.
(c) The
amount of Taxation chargeable to the Company has not been affected
by any concession, arrangements, agreement or other formal or
informal arrangement with any Governmental Body (not being a
concession, agreement or arrangement available to companies
generally). The Company is not subject to a special Tax regime. The
Company is not required to include any amounts in income, or to
exclude any items of deduction in a taxable period beginning after
the Closing Date as a result of (i) an instalment sale or open
transaction arising in a taxable period ending on or before the
Closing Date; (ii) a prepaid amount received, or paid,
in
8
a taxable
period ending on or before the Closing Date; (iii) deferred
gains that could be recognized in a taxable period ending after the
Closing Date; or (iv) any similar item of deferred income or
expense.
(d) In
relation to Tax, the Company has not been subject to and is not
currently subject to any investigation, audit or visit by any
Governmental Body, and, to the Sellers’ Knowledge, no such
investigation, audit or visit is planned by any Governmental
Body.
(e) Since
its incorporation, the Company has not been involved in any
Taxation controversy and/or litigation with or against any
Governmental Body.
(f) The
Company has made all deductions and/or withholdings in respect, or
in account, of any Taxation from any payments made by the Company
that it is obliged or entitled to have made and has accounted in
full to the appropriate authority for all amounts so deducted
and/or withheld.
(g) The
Company has not received any notice from any Governmental Body that
required or will require the Company to withhold Taxation from any
payment made since the Balance Sheet Date in respect of which such
withheld Taxation has not been accounted for in full to the
appropriate authority.
(h) The
Company has not claimed or been granted exemptions from Taxation
that may give rise to the assessment and/or payment of Taxation in
connection with any transactions involving the Company, including
but not limited to this Agreement, reorganisations, mergers and/or
disposals of the Company.
(i) All
applications by the Company for governmental subsidies, which have
been made or are reflected in the Balance Sheet have been duly and
correctly made and no refunds and no interest, penalties or
additions regarding such refunds are or will be due in respect of
governmental subsidies.
(i) has
always been resident, for Tax purposes, in the
Netherlands;
(ii) is
not and has never been resident, for Tax purposes, in any other
jurisdiction;
(iii) does
not have and has never had a taxable presence outside the
Netherlands; and
(iv) is
not deemed to have and has never been deemed to have had a taxable
presence outside the Netherlands.
(k) No
Taxation, for which any other person or entity is or may be liable,
will be charged in any way to the Company, and the Company is not a
party to or bound by any Tax indemnity, Tax sharing, Tax allocation
or similar agreement.
9
(l) Each
transaction between the Sellers or any Affiliate of the Sellers on
the one hand and the Company on the other hand is and has been done
at an arm’s length basis.
(m) The
Company is not liable for Taxation imposed on or due by any third
party, including, without limitation, any sub-contractor, the
Sellers or any Affiliate of the Sellers, except to the extent that
full provision has been made in the Financial Statements of the
Company.
(n) Other
than by their own expiration over time, there is no limitation on
the utilization by the Company of its net operating losses,
built-in losses, Tax credits or similar items under the Tax laws of
any jurisdiction (other than any such limitations arising as a
result of the consummation of the Contemplated
Transactions).
(o) The
Company does not own any interest in any entity that is
characterized as a partnership for Tax purposes.
(p) There
are no Tax liens or other Encumbrances with respect to Taxation
upon any of the Assets of the Company, other than Permitted
Encumbrances.
(q) The
Company has delivered or made available to Purchaser in the Data
Room for inspection (i) complete and correct copies of all Tax
Returns of the Company relating to Taxation and (ii) complete and
correct copies of all documents from any Governmental Body received
by or agreed to by or on behalf of the Company relating to Taxation
since the Company’s formation.
3.12 No
Material Adverse Change . Since the date of the Balance Sheet,
there has not been a Material Adverse Effect.
3.13
Pensions. The Company has no, and has never had any
retirement benefit schemes, early retirement schemes, pre-pension
schemes or other pension arrangements, relating to the Business
(the “ Pension Schemes ”), in operation
or proposed.
3.14 Legal
Proceedings; Orders .
(a) There
is no pending Proceeding:
(i) that
has been commenced by or against the Company or that otherwise
relates to or may affect the business of, or any of the assets
owned or used by, the Company; or
(ii) that
challenges, or that may have the effect of preventing, delaying,
making illegal, or otherwise interfering with, any of the
Contemplated Transactions.
To
Sellers’ Knowledge, (1) no such Proceeding has been
Threatened, and (2) no event has occurred or circumstance
exists that may give rise to or serve as a basis for the
commencement of any such Proceeding. Seller Parties have made
available to Purchaser in the Data Room copies of all pleadings,
correspondence, and other documents relating to each Proceeding
listed in Part 3.14(a) of the Seller Parties Disclosure
Schedule. The Proceedings listed in Part 3.14(a)
10
of the Seller
Parties Disclosure Schedule could not reasonably be expected to
have a Material Adverse Effect.
(b) There
is no Order to which the Company, or any of the assets owned or
used by the Company, is subject.
(c) No
officer, director, agent, or employee of the Company is subject to
any Order that prohibits such officer, director, agent, or employee
from engaging in or continuing any conduct, activity, or practice
relating to the business of the Company.
(d) The
Company is, and at all times has been, in full compliance with all
of the terms and requirements of each Order to which it, or any of
the assets owned or used by it, is or has been subject.
(e) No
event has occurred or circumstance exists that may constitute or
result in (with or without notice or lapse of time) a violation of
or failure to comply with any term or requirement of any Order to
which the Company, or any of the assets owned or used by the
Company, is subject.
(f) The
Company has not received, at any time, any notice or other
communication (whether oral or written) from any Governmental Body
or any other Person regarding any actual, alleged, possible, or
potential violation of, or failure to comply with, any term or
requirement of any Order to which the Company, or any of the assets
owned or used by the Company, is or has been subject.
3.15 Absence of
Certain Changes and Events . Except as set forth in
Part 3.15 of the Seller Parties Disclosure Schedule, since the
Balance Sheet Date, the Company has conducted its business only in
the Ordinary Course of Business and none of the following actions
or events has occurred:
(a) any
material loss, damage or destruction to, or any material
interruption in the use of, any of the assets of the Company
(whether or not covered by insurance) that has had or could
reasonably be expected to have a Material Adverse
Effect;
(b) (i) any
declaration, accrual, set aside or payment of any dividend or any
other distribution in respect of any shares of capital stock of the
Company, or (ii) any repurchase, redemption or other
acquisition by the Company of any shares of capital stock or other
securities;
(c) any
sale, issuance or grant, or authorization of the issuance of,
(i) shares or other securities of the Company, (ii) any
option, warrant or right to acquire any shares or any other
securities of the Company, or (iii) any instrument convertible
into or exchangeable for shares or other securities of the
Company;
(d) any
amendment or waiver of any of the rights of the Company under any
share purchase agreement;
11
(e) any
amendment to any Organizational Document of the Company, any
merger, consolidation, share exchange, business combination,
recapitalization, reclassification of shares, share split, reverse
share split or similar transaction involving the
Company;
(f) any
creation of any Subsidiary of the Company or acquisition by the
Company of any equity interest or other interest in any other
Person;
(g) any
capital expenditure by the Company which, when added to all other
capital expenditures made on behalf of the Company since the
Balance Sheet Date, exceeds €
10,000 in the aggregate;
(h) except
in the Ordinary Course of Business, any action by the Company to
(i) enter into or suffer any of the assets owned or used by it
to become bound by any Material Contract (as defined in
Section 3.16 ), or (ii) amend or terminate, or
waive any material right or remedy under, any Material
Contract;
(i) any
(i) acquisition, lease or license by the Company of any
material right or other material asset from any other Person,
(ii) sale or other disposal or lease or license by the Company
of any material right or other material asset to any other Person,
or (iii) waiver or relinquishment by the Company of any right,
except for rights or other assets acquired, leased, licensed or
disposed of in the Ordinary Course of Business;
(j) any
write-off as uncollectible, or establishment of any extraordinary
reserve with respect to, any Indebtedness of the
Company;
(k) any
pledge of any assets of or sufferance of any of the assets of the
Company to become subject to any Encumbrance, except for Permitted
Encumbrances and pledges of immaterial assets made in the Ordinary
Course of Business;
(l) any
(i) loan by the Company to any Person, or (ii) the
incurrence or guarantee by the Company of any Indebtedness by the
Company;
(m) any
(i) adoption, establishment, entry into or amendment by the
Company of any Pension Scheme or (ii) payment of any bonus or
any profit sharing or similar payment to, or material increase in
the amount of the wages, salary, commissions, fringe benefits or
other compensation or remuneration payable to, any of the directors
or officers of the Company;
(n) any
change of the methods of accounting or accounting practices of the
Company in any material respect;
(o) any
material Tax election by the Company;
(p) any
commencement or settlement of any Proceeding by the Company;
and
(q) any
agreement or commitment to take any of the actions referred to in
clauses (c) through (p) above.
12
3.16 Contracts;
No Defaults.
(a) Part 3.16(a)
of the Seller Parties Disclosure Schedule contains a complete and
accurate list, and Seller Parties have made available to Purchaser
in the Data Room true and complete copies of, each Contract, other
instrument or document (including of any amendments) to which the
Company is a party or by which its assets are subject or
bound:
(i) with
any director, officer or Affiliate of the Company;
(ii) evidencing,
governing or relating to Indebtedness;
(iii) not
entered into in the Ordinary Course of Business that involves
expenditures or receipts;
(iv) that
in any way purports to restrict the business activity of the
Company or any of its Affiliates or to limit the freedom of the
Company or any of its Affiliates to engage in any line of business
or to compete with any Person or in any geographic area or to hire
or retain any Person;
(v) relating
to the employment of, or the performance of services by, any
employee or consultant, or pursuant to which the Company is or may
become obligated to make any severance, termination or similar
payment to any current or former employee or director; or pursuant
to which the Company is or may become obligated to make any bonus
or similar payment (other than payments constituting base salary)
to any current or former employee or director;
(vi) (A) relating
to the acquisition, transfer, development, sharing or license of
any Proprietary Rights (except for any Contract pursuant to which
(1) any Proprietary Rights is licensed to the Company under
any third party software license generally available to the public,
or (2) any Proprietary Rights is licensed by the Company to
any Person on a non exclusive basis); or (B) of the type
referred to in Section 3.20(d) ;
(vii) providing
for indemnification of any officer, director, employee or
agent;
(viii) (A) relating
to the acquisition, issuance, voting, registration, sale or
transfer of any securities, (B) providing any Person with any
preemptive right, right of participation, right of maintenance or
any similar right with respect to any securities, or
(C) providing the Company with any right of first refusal with
respect to, or right to repurchase or redeem, any
securities;
(ix) incorporating
or relating to any guaranty, any warranty or any indemnity or
similar obligation, except for Contracts substantially identical to
the standard forms of end user licenses made available by Seller
Parties to Purchaser in the Data Room;
(x) relating
to any currency hedging;
13
(xi) (A) imposing
any confidentiality obligation on the Company or any other Person,
or (B) containing “standstill” or similar
provisions;
(xii) (A) to
which any Governmental Body is a party or under which any
Governmental Body has any rights or obligations, or
(B) directly or indirectly benefiting any Governmental Body
(including any subcontract or other Contract between the Company
and any contractor or subcontractor to any Governmental
Body);
(xiii) contemplating
or involving the payment or delivery of cash or other consideration
in an amount or having a value in excess of €
5,000 in the aggregate, or
contemplating or involving the performance of services having a
value in excess of €
5,000 in the aggregate;
and
(xiv) any
other Contract, if a breach of such Contract could reasonably be
expected to have a Material Adverse Effect.
(b) Each
of the foregoing is a “ Material Contract
.”
(i) Each
Material Contract is valid and in full force and effect, and is
enforceable against the Company in accordance with its terms,
subject to bankruptcy and other similar Legal Requirements of
general applicability relating to or affecting creditors’
rights and to general equity principles.
(ii) The
Company has not violated or breached, or committed any default
under, any Material Contract, except for violations, breaches and
defaults that have not had and would not reasonably be expected to
have a Material Adverse Effect; and, to Sellers’ Knowledge,
no other Person has violated or breached, or committed any default
under, any Material Contract, except for violations, breaches and
defaults that have not had and would not reasonably be expected to
have a Material Adverse Effect.
(iii) Except
as set forth on Part 3.16(b) of the Seller Parties Disclosure
Schedule, to Sellers’ Knowledge, no event has occurred, and
no circumstance or condition exists, that (with or without notice
or lapse of time) will or would reasonably be expected to,
(A) result in a violation or breach of any of the provisions
of any Material Contract, (B) give any Person the right to
declare a default or exercise any remedy under any Material
Contract, (C) give any Person the right to receive or require
a rebate, chargeback, penalty or change in delivery schedule under
any Material Contract, (D) give any Person the right to
accelerate the maturity or performance under any Material Contract,
(E) result in the disclosure, release or delivery of the
Company Source Code, or (F) give any Person the right to
cancel, terminate or modify any Material Contract, except in each
such case for defaults, acceleration rights, termination rights and
other rights that have not had and would not reasonably be expected
to have a Material Adverse Effect.
(iv) The
Company has not received any notice or other communication
regarding any actual or possible violation or breach of, or default
under, any Material Contract, except in each such case for
defaults, acceleration rights, termination rights and other rights
that have not had and would not reasonably be expected to have a
Material Adverse Effect.
14
(a) Seller
Parties have made available to Purchaser in the Data
Room:
(i) true
and complete copies of all policies of insurance to which the
Company is a party or under which the Company, or any director of
the Company, in his capacity as such, is or has been covered at any
time preceding the date of this Agreement;
(ii) true
and complete copies of all pending applications for policies of
insurance; and
(iii) any
statement by the auditor of the Company’s financial
statements with regard to the adequacy of such entity’s
coverage or of the reserves for claims.
(i) has
no self-insurance arrangements by or affecting the Company,
including any reserves established thereunder;
(ii) has
not concluded contracts or arrangements, other than a policy of
insurance, for the transfer or sharing of any risk by the
Company;
(iii) has
made available to Purchaser in the Data Room all obligations of the
Company to third parties with respect to insurance (including such
obligations under leases and service agreements) and identifies the
policy under which such coverage is provided; and
(iv) has
not suffered any loss experience or received any claim under any
policy for the current policy year.
(c) All
policies to which the Company is a party or that provide coverage
to the Company, or any director or officer of the Company in his
capacity as such:
(i) are
valid, outstanding, and enforceable;
(ii) are
issued by an insurer that is financially sound and
reputable;
(iii) taken
together, provide adequate insurance coverage for the assets and
the operations of the Company for all risks normally insured
against by a Person carrying on the same business or businesses as
the Company;
(iv) are
sufficient for compliance with all Legal Requirements and Contracts
to which the Company is a party or by which any of them is
bound;
(v) will
continue in full force and effect following the consummation of the
Contemplated Transactions; and
(vi) do
not provide for any retrospective premium adjustment or other
experienced-based liability on the part of the Company.
15
(d) The
Company has not received (A) any refusal of coverage or any
notice that a defense will be afforded with reservation of rights,
or (B) any notice of cancellation or any other indication that
any insurance policy is no longer in full force or effect or will
not be renewed or that the issuer of any policy is not willing or
able to perform its obligations thereunder.
(e) The
Company has paid all premiums due, and has otherwise performed all
of its respective obligations, under each policy to which the
Company is a party or that provides coverage to the Company or
director thereof.
(f) The
Company has given notice to the insurer of all claims that may be
insured under any policy provided by such insurer.
3.18
Environmental Matters .
(a) The
Company is, and at all times has been, in material compliance with,
and has not been and is not in violation of or liable under, any
Environmental Law. To Sellers’ Knowledge, there is no actual
order, written notice, or other written communication from, nor has
any order, notice, or other communication been Threatened from
(i) any Governmental Body or private citizen, or (ii) the
current or prior owner or operator of any Facilities, of any actual
or potential violation or failure to comply with any Environmental
Law, or of any actual or Threatened obligation to undertake or bear
the cost of any Environmental, Health, and Safety Liabilities with
respect to any of the Facilities or any other properties or assets
(whether real, personal, or mixed) in which the Company had an
interest, or with respect to any property or Facility at or to
which Hazardous Materials were generated, manufactured, refined,
transferred, imported, used, or processed by the Company, or any
other Person for whose conduct they are or may be held responsible,
or from which Hazardous Materials have been transported, treated,
stored, handled, transferred, disposed, recycled, or
received.
(b) There
are no pending or, to Sellers’ Knowledge, Threatened claims,
Encumbrances, or other restrictions of any nature, resulting from
any Environmental, Health, and Safety Liabilities or arising under
or pursuant to any Environmental Law, with respect to or affecting
any of the Facilities or any other properties and assets (whether
real, personal, or mixed) in which the Company has or had an
interest.
(c) The
Company has not received, any citation, directive, inquiry, notice,
Order, summons, warning, or other communication that relates to
Hazardous Activity, Hazardous Materials, or any alleged, actual, or
potential violation or failure to comply with any Environmental
Law, or of any alleged, actual, or potential obligation to
undertake or bear the cost of any Environmental, Health, and Safety
Liabilities with respect to any of the Facilities or any other
properties or assets (whether real, personal, or mixed) in which
the Company had an interest, or with respect to any property or
facility to which Hazardous Materials generated, manufactured,
refined, transferred, imported, used, or processed by the Company,
or any other Person for whose conduct they are or may be held
responsible, have been transported, treated, stored, handled,
transferred, disposed, recycled, or received.
16
(d) The
Company has no Environmental, Health, and Safety Liabilities with
respect to the Facilities or, with respect to any other properties
and assets (whether real, personal, or mixed) in which the Company
(or any predecessor), has or had an interest, or at any property
geologically or hydrologically adjoining the Facilities or any such
other property or assets.
(e) Except
as set forth on Part 3.18(e) of the Seller Parties Disclosure
Schedule, there are no Hazardous Materials present on or in the
Environment at the Facilities or at any geologically or
hydrologically adjoining property, including any Hazardous
Materials contained in barrels, above or underground storage tanks,
landfills, land deposits, dumps, equipment (whether moveable or
fixed) or other containers, either temporary or permanent, and
deposited or located in land, water, sumps, or any other part of
the Facilities or such adjoining property, or incorporated into any
structure therein or thereon. The Company has not permitted or
conducted any, and to Sellers’ Knowledge there is no,
Hazardous Activity conducted with respect to the Facilities or any
other properties or assets (whether real, personal, or mixed) in
which the Company has or had an interest.
(f) There
has been no Release or, to Sellers’ Knowledge, Threat of
Release, of any Hazardous Materials at or from the Facilities or at
any other locations where any Hazardous Materials were generated,
manufactured, refined, transferred, produced, imported, used, or
processed from or by the Facilities, or from or by any other
properties and assets (whether real, personal, or mixed) in which
the Company has or had an interest, or any geologically or
hydrologically adjoining property.
(g) The
Company has delivered to Purchaser true and complete copies and
results of any reports, studies, analyses, tests, or monitoring
possessed or initiated by the Company pertaining to Hazardous
Materials or Hazardous Activities in, on, or under the Facilities,
or concerning compliance by the Company with Environmental
Laws.
3.19
Employees . The Company has no employees, nor has it ever
had any employees, prior to the Closing Date. The Company is not a
party to any collective labour agreement.
3.20
Intellectual Property .
(a) With
respect to Proprietary Rights of the Company:
(i) Part 3.20(a)(i)(A)
of the Seller Parties Disclosure Schedule lists all of the Patents
owned by the Company, setting forth in each case the jurisdictions
in which Issued Patents have been issued and Patent Applications
have been filed. Part 3.20(a)(i)(B) of the Seller Parties
Disclosure Schedule lists all of the Patents in which the Company
has any right, title or interest (including without limitation
interest acquired through a license or other right to use) other
than those owned by the Company, setting forth in each case the
jurisdictions in which the Issued Patents have been issued and
Patent Applications have been filed, and the nature of the right,
title or interest held by the Company. Except as set forth on
Part 3.20(a)(i)(A) of the Seller Parties Disclosure Schedule,
the Company has obtained a Patent with respect to each
Product;
(ii) Part 3.20(a)(ii)(A)
of the Seller Parties Disclosure Schedule lists all of the
Registered Trademarks owned by the Company, setting forth in each
case the jurisdictions in which Registered Trademarks have been
registered and trademark applications for registration
17
have been
filed. Part 3.20(a)(ii)(B) of the Seller Parties Disclosure
Schedule lists all of the Registered Trademarks in which the
Company has any right, title or interest, other than those owned by
the Company (including without limitation interest acquired through
a license or other right to use), setting forth in each case the
jurisdictions in which Registered Trademarks have been registered
and trademark applications for registration have been filed, and
the nature of the right, title or interest held by the
Company;
(iii) Part 3.20(a)(iii)(A)
of the Seller Parties Disclosure Schedule lists all of the
Registered Copyrights owned by the Company, setting forth in each
case the jurisdictions in which Copyrights have been registered and
applications for copyright registration have been filed. Part
3.20(a)(iii)(B) of the Seller Parties Disclosure Schedule lists all
of the Registered Copyrights in which the Company has any right,
title or interest, other than those owned by the Company (including
without limitation interest acquired through a license or other
right to use), setting forth in each case the jurisdictions in
which the Registered Copyrights have been registered and
applications for copyright registration have been filed, and the
nature of the right, title or interest held by the Company;
and
(iv) The
Company has good and valid title to all of the Company Proprietary
Rights identified in Parts 3.20(a)(i)(A), 3.20(a)(ii)(A) and
3.20(a)(iii)(A) of the Seller Parties Disclosure Schedule and all
Trade Secrets owned by the Company, free and clear of all
Encumbrances, except for Permitted Encumbrances. The Company has a
valid right to use, license and otherwise exploit all Proprietary
Rights identified in Parts 3.20(a)(i)(B), 3.20(a)(ii)(B), and
3.20(a)(iii)(B) of the Seller Parties Disclosure Schedule and all
Trade Secrets used by the Company, other than those owned by the
Company (including without limitation interest acquired through a
license or other right to use). Except as set forth on
Part 3.20(a)(iv) of the Seller Parties Disclosure Schedule,
the Company Proprietary Rights identified in Part 3.20(a) of
the Seller Parties Disclosure Schedule, together with the Trade
Secrets used by the Company, constitutes (A) all Proprietary
Rights used or proposed as of the Effective Date to be used in the
business of the Company as conducted prior to or on the Effective
Date or as proposed to be conducted by Company as of the Effective
Date and (B) all Proprietary Rights necessary or appropriate
to make, use, offer for sale, sell or import the
Product(s).
(b) Part 3.20(b)
of the Seller Parties Disclosure Schedule lists all oral and
written contracts, agreements, licenses and other arrangements
relating to the Company Proprietary Rights or the Product(s), as
follows:
(i) Part 3.20(b)(i)
lists: (A) any agreement granting any right to make, have
made, manufacture, use, sell, offer to sell, import, export, or
otherwise distribute any Product(s), with or without the right to
sublicense the same, on an exclusive basis; (B) any license of
Proprietary Rights to or from the Company, with or without the
right to sublicense the same, on an exclusive basis; (C) joint
development agreements; (D) any agreement by which the Company
grants any ownership right to the Company Proprietary Rights owned
by the Company; (E) any agreement under which the Company
undertakes any ongoing royalty or payment obligations with respect
to an Company Proprietary Right; (F) any agreement under which
the Company grants an option relating to the Company Proprietary
Rights; (G) any agreement under which any party is granted any
right to access Company Source Code or to use Company Source Code
to create derivative works of the Products; (H) any Agreement
pursuant
18
to which the
Company has deposited or is required to deposit with an escrow
agent or any other Person the Company Source Code, and further
describes whether the execution of this Agreement or the
consummation of any of the transactions contemplated hereby could
reasonably be expected to result in the release or disclosure of
the Company Source Code; and (I) any agreement or other
arrangement limiting any of the Company’s ability to transact
business in any market, field or geographical area or with any
Person, or that restricts the use, transfer, delivery or licensing
of Company Proprietary Rights (or any tangible embodiment
thereof);
(ii) Part 3.20(b)(ii)
of the Seller Parties Disclosure Schedule lists all licenses,
sublicenses and other agreements to which the Company is a party
and pursuant to which the Company is authorized to use any
Proprietary Rights owned by any Person, excluding standardized
nonexclusive licenses for “off the shelf” or other
software widely available through regular commercial distribution
channels on standard terms and conditions and were obtained by the
Company in the Ordinary Course of Business. Except as set forth in
3.20(b)(iii) of the Seller Parties Disclosure Schedule, there are
no royalties, fees or other amounts payable by the Company to any
Person by reason of the ownership, use, sale or disposition of
Company Proprietary Rights;
(iii) Except
as set forth in Part 3.20(b)(iii) of the Seller Parties
Disclosure Schedule, the Company has not entered into any written
or oral contract, agreement, license or other arrangement to
indemnify any other person against any charge of infringement of
the Company Proprietary Rights, other than indemnification
provisions contained in standard sales or agreements to customers
or end users arising in the Ordinary Course of Business, the forms
of which have been delivered to Purchaser or its
counsel;
(iv) Part 3.20(b)(iv)
of the Seller Parties Disclosure Schedule lists any Product that
contains any software that may be subject to an open source or
general public license, a description of such Product and the open
source or general public license applicable to such Product. Except
as set forth in Part 3.20(b)(iv) of the Seller Parties
Disclosure Schedule, none of the Products contains any software
that may be subject to an open source or general public license;
and
(v) There
are no outstanding obligations other than as disclosed in
Part 3.20(b) of the Seller Parties Disclosure Schedule to pay
any amounts or provide other consideration to any other Person in
connection with the Company Proprietary Rights (or any tangible
embodiment thereof).
(c) Except
as set forth in Part 3.20(c) of the Seller Parties Disclosure
Schedule:
(i) The
Company does not jointly own, license or claim any right, title or
interest with any other Person of the Company Proprietary Rights.
No current or former officer, manager, director, stockholder,
member, employee, consultant or independent contractor of the
Company has any right, title or interest in, to or under the
Company Proprietary Rights in which the Company has (or purports to
have) any right, title or interest that has not been exclusively
assigned, transferred or licensed to Company;
19
(ii) No
Person has asserted or Threatened a claim, nor, to Sellers’
Knowledge, are there any facts which could give rise to a claim,
which would adversely affect the Company’s ownership rights
to, or rights under, the Company Proprietary Rights, or any
contract, agreement, license or and other arrangement under which
the Company claims any right, title or interest under the Company
Proprietary Rights or restricts in any material respect the use,
transfer, delivery or licensing by the Company of the Company
Proprietary Rights or Products;
(iii) The
Company is not subject to any proceeding or outstanding decree,
order, judgment or stipulation restricting in any manner the use,
transfer or licensing of the Company Proprietary Rights by the
Company, the use, transfer or licensing of any Product by the
Company, or which may affect the validity, use or enforceability of
the Company Proprietary Rights; and
(iv) To
Sellers’ Knowledge, no Company Proprietary Rights have been
infringed or misappropriated by any Person and there is no
unauthorized use, disclosure or misappropriation of the Company
Proprietary Rights by any current or former officer, manager,
director, stockholder, member, employee, consultant or independent
contractor of the Company.
(d) Except
as set forth in Part 3.20(d) of the Seller Parties Disclosure
Schedule:
(i) all
Patents in which the Company has any right, title or interest have
been duly filed or registered (as applicable) with the applicable
Governmental Body, and maintained, including the submission of all
necessary filings and fees in accordance with the legal and
administrative requirements of the appropriate Governmental Body,
and have not lapsed, expired or been abandoned;
(ii) (A) all
Patents in which the Company has any right, title or interest,
disclose patentable subject matter, have been prosecuted in good
faith and are in good standing, (B) there are no inventorship
challenges to any such Patents, (C) no interference has been
declared or provoked relating to any such Patents, (D) all
Issued Patents in which the Company has any right, title or
interest are valid and enforceable, and (E) all maintenance
and annual fees have been fully paid, and all fees paid during
prosecution and after issuance of any patent have been paid in the
correct entity status amounts, with respect to Issued Patents in
which the Company has any right, title or interest;
(iii) To
Sellers’ Knowledge, there is no material fact with respect to
any Patent Application in which the Company has any right, title or
interest that would
|